Trial Profile
A Prospective, Randomised, Controlled, Open-label, Multicentre Phase III Study to Evaluate Efficacy and Safety of Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-Edotreotide Compared to Targeted Molecular Therapy With Everolimus in Patients With Inoperable, Progressive, Somatostatin Receptor-positive (SSTR+), Neuroendocrine Tumours of Gastroenteric or Pancreatic Origin (GEP-NET)
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 04 Dec 2023
Price :
$35
*
At a glance
- Drugs Lu-177 octreotide (Primary) ; Everolimus
- Indications Gastrointestinal cancer; Neuroendocrine tumours; Pancreatic cancer
- Focus Registrational; Therapeutic Use
- Acronyms COMPETE
- Sponsors ITM Solucin
- 11 Apr 2022 According to a itm Group media release,Prof. Jaume Capdevila, Principal Investigator of COMPETE at the University Hospital Vall d'Hebron in Barcelona, Spain
- 11 Apr 2022 Status changed from recruiting to active, no longer recruiting.
- 09 Mar 2022 According to a itm Group media release, COMPOSE trial builds upon ITMs first ongoing phase III clinical trial, COMPETE (NCT03049189), examining patients with grade 1 and grade 2, GEP-NETs.